What really separates roflumilast (Zoryve) from other PDE4 inhibitors — and why does it matter for your patients with atopic dermatitis, psoriasis, or seborrheic dermatitis? In this episode, Dr. Ted Lane sits down with Dr. Chris Bunick, Associate Professor of Dermatology at Yale School of Medicine and Editor-in-Chief of Dermatology Times, for a deep dive into the biochemistry, formulation science, and clinical implications behind this breakthrough topical treatment.

In this episode, you'll learn:

• Why roflumilast binds PDE4 with 200x more potency than apremilast — and 1,000x more than crisaborole
• How cyclic AMP inhibition controls upstream cytokine pathways (TH1, TH2, TH17) across multiple inflammatory skin diseases
• The science behind the Crotofos emulsifier — and why the right emulsifier protects the skin barrier instead of stripping ceramides
• Why formulating at pH 5.5 matters for filaggrin, keratin, and barrier integrity
• How the roflumilast foam is specifically engineered for scalp conditions and hair-bearing areas
• What's next in topical formulation innovation — from targeted dermal delivery to longevity skincare

Whether you're a dermatologist, resident, PA, NP, or skincare enthusiast who wants to understand the why behind cutting-edge topicals, this episode is packed with clinical and scientific insight you won't find anywhere else.

🎙️ This episode is sponsored by Arcutis Biotherapeutics, maker of roflumilast cream and foam.

📧 Send your questions to: questions@scienceofskinnsummit.com

📅 Science of Skin Summit — September 19–21, Austin, TX

📅 Longevity Meeting — February 19 - 21, Scottsdale, AZ

Subscribe, leave a 5-star review, and follow Dr. Bunick's podcast: ABCDs in Dermatology.

Disclaimer: This podcast is not intended to provide diagnosis, treatment, or medical advice. Content provided in this podcast is for educational purposes only. Please consult with a physician regarding any health-related diagnosis or treatment.